8-KLeadership Changes

BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Mar 17, 2022)

Filed March 17, 2022For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb Company (BMY) has announced a change in its principal officer role for Senior Vice President and Controller. Effective April 25, 2022, Sharon Greenlees will assume this position, succeeding Karen Murphy Santiago, who will depart the company by May 1, 2022. Ms. Greenlees brings extensive financial experience from her recent role at AbbVie Inc. as Vice President and Controller, R&D Finance and Operations, and prior positions including Head of Supply Chain Finance and Vice President of Investor Relations. This executive transition in a key financial leadership role is the primary focus of this 8-K filing. Investors should note that Ms. Greenlees has a strong background in accounting and is a Certified Public Accountant. The filing also confirms that there are no undisclosed arrangements, understandings, family relationships, or related-party transactions concerning Ms. Greenlees's appointment, indicating a standard executive onboarding process.

Key Highlights

  • 1Appointment of Sharon Greenlees as Senior Vice President and Controller, effective April 25, 2022.
  • 2Departure of current Senior Vice President and Controller, Karen Murphy Santiago, by May 1, 2022.
  • 3Ms. Greenlees joins BMY from AbbVie Inc., where she most recently served as Vice President and Controller, R&D Finance and Operations.
  • 4Ms. Greenlees possesses a strong financial background with experience in investor relations, supply chain finance, and pricing.
  • 5Ms. Greenlees holds a B.S. in Accounting and is a Certified Public Accountant.
  • 6The filing indicates no undisclosed arrangements, understandings, family relationships, or related-party transactions concerning Ms. Greenlees's appointment.

Frequently Asked Questions

Sharon Greenlees has been appointed as the new Senior Vice President and Controller, effective April 25, 2022.

The filing states that Ms. Karen Murphy Santiago will leave the Company by May 1, 2022. No specific reason for her departure is provided in this report.

Ms. Greenlees has significant financial experience, most recently serving as Vice President and Controller, R&D Finance and Operations at AbbVie Inc. She also held roles in Investor Relations, Supply Chain Finance, and Pricing.

The filing explicitly states that Ms. Greenlees is not a party to any arrangements or understandings regarding her selection, nor are there any family relationships with existing directors or officers, or any transactions requiring disclosure under Item 404(a) of Regulation S-K.